News
Outlining Exercise as a "Biologically Interventional Therapy" for Cancer
2+ day, 36+ min ago (171+ words) Goodyear is an integrative medicine physician at the Williams Cancer Institute. There's research that shows that it does, but then there's research that shows how it does. It's not just one thing to show the "what," but the "how." Now,…...
Quizartinib Regimen Appears Effective in FLT3-ITD+ AML Trial
2+ day, 3+ hour ago (132+ words) Data from a phase 2 trial show that quizartinib plus omacetaxine mepesuccinate may better position patients to proceed to consolidative transplantation. "The QUIZOM combination therapy provides an effective and feasible treatment option for patients with FLT3-mutated AML who are unfit for…...
Perioperative Enfortumab Vedotin Combo Has Potential as SOC in Cisplatin-Ineligible MIBC
7+ mon, 5+ day ago (19+ words) Enfortumab vedotin plus pembrolizumab enhanced survival rates for patients with muscle-invasive bladder cancer not eligible for cisplatin chemotherapy....
CHMP Gives Positive Opinion for Pembrolizumab-Containing Combo in MIBC Type
2+ day, 3+ hour ago (392+ words) Event-free survival, overall survival, and pathologic complete rate data from the phase 3 KEYNOTE-905 trial support the agency's decision. A combination containing pembrolizumab (Keytruda) and enfortumab vedotin-ejfv (Padcev) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products…...
FDA OKs Updated Guardant360 Liquid CDx with Expanded Molecular Profiling
2+ day, 3+ hour ago (135+ words) The FDA has approved the updated Guardant360 Liquid CDx, a blood-based cancer test combining genomic and epigenomic analysis, across multiple tumors. The newly approved version of the Guardant360 Liquid CDx panel evaluates a genomic footprint that is 100 times wider than the earlier…...
Sacituzumab Tirumotecan Meets PFS End Point as 1 L Option in Advanced TNBC
2+ day, 4+ hour ago (250+ words) Sac-TMT demonstrated a significant improvement in PFS vs chemotherapy as first-line treatment for unresectable locally recurrent or metastatic TNBC. This result marks the first registrational phase 3 study of sac-TMT to demonstrate a positive outcome in the first-line TNBC setting'a population…...
Dato-DXd May Be Next SOC in First-Line TNBC
7+ mon, 4+ day ago (16+ words) Datopotamab deruxtecan significantly enhanced survival rates in first-line treatment for metastatic triple-negative breast cancer....
FDA Approves Dato-DXd for Metastatic Triple-Negative Breast Cancer
2+ day, 5+ hour ago (322+ words) The approval, based on the phase 3 TROPION-Breast02 trial, marks a significant shift in the first-line treatment of patients with m TNBC. The FDA has approved datopotamab deruxtecan-dlnk (dato-DXd; Datroway) for the treatment of adult patients with unresectable or metastatic triple-negative…...
99 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results From the Phase 3 EMBER-3 Trial
3+ day, 47+ min ago (21+ words) Cancer Network is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers....
100 Imlunestrant Plus Abemaciclib Versus Fulvestrant Plus Abemaciclib in Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2) Advanced Breast Cancer (ABC): An Indirect Treatment Comparison (ITC) of Three Phase 3 Trials
3+ day, 57+ min ago (21+ words) Cancer Network is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers....